Drugs / Alkotinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04032821 | Nov → Dec 2019 | non-small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03607188 | Oct 2018 → Oct 2022 | non-small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04211922 | Jan 2020 → Oct 2022 | non-small cell lung carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alkotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04211922 ↗ |
| Action | Inhibit | “selectively inhibits anaplastic lymphoma Kinase and proto-oncogene protein ROS1” NCT04032821 ↗ |
| Route | Oral | “ZG0418 200mg/day,oral” NCT03607188 ↗ |
| Target | ALK | “Alkotinib is an insulin receptor tyrosine kinase inhibitor that selectively inhibits anaplastic lymphoma Kinase and proto-oncogene protein ROS1。Alkotinib is expected to be used...” NCT04032821 ↗ |
| Target | ROS1 | “Alkotinib is an insulin receptor tyrosine kinase inhibitor that selectively inhibits anaplastic lymphoma Kinase and proto-oncogene protein ROS1。Alkotinib is expected to be used...” NCT04032821 ↗ |